SG10201604566QA - Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors - Google Patents

Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors

Info

Publication number: SG10201604566QA
Authority: SG; Singapore
Prior art keywords: preventing; methods; inhibiting binding; treating certain; certain disorders
Prior art date: 2011-12-13

Application number

SG10201604566QA

Inventor

Andreas Hohlbaum

Laurent Audoly

Original Assignee

Pieris Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-13

Filing date

2012-12-12

Publication date

2016-07-28

2012-12-12 Application filed by Pieris Ag filed Critical Pieris Ag

2016-07-28 Publication of SG10201604566QA publication Critical patent/SG10201604566QA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Marine Sciences & Fisheries (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dispersion Chemistry (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

SG10201604566QA 2011-12-13 2012-12-12 Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors SG10201604566QA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161570018P	2011-12-13	2011-12-13

Publications (1)

Publication Number	Publication Date
SG10201604566QA true SG10201604566QA (en)	2016-07-28

Family

ID=47552959

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201604566QA SG10201604566QA (en)	2011-12-13	2012-12-12	Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
SG11201402992SA SG11201402992SA (en)	2011-12-13	2012-12-12	Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201402992SA SG11201402992SA (en)	2011-12-13	2012-12-12	Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors

Country Status (13)

Country	Link
US (6)	US9572863B2 (en)
EP (3)	EP3453400B1 (en)
JP (5)	JP6163162B2 (en)
CN (2)	CN103998053B9 (en)
AU (1)	AU2012350660B2 (en)
CA (1)	CA2858962C (en)
DK (2)	DK2790719T3 (en)
ES (2)	ES2863410T3 (en)
HU (2)	HUE054342T2 (en)
PL (2)	PL3453400T3 (en)
SG (2)	SG10201604566QA (en)
TR (1)	TR201901826T4 (en)
WO (1)	WO2013087660A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE043835T2 (en)	2010-06-08	2019-09-30	Pieris Pharmaceuticals Gmbh	Tear lipocalin muteins binding il-4 r alpha
DK2790719T3 (en)	2011-12-13	2019-02-11	Pieris Pharmaceuticals Gmbh	Methods for preventing or treating certain diseases by inhibiting the binding of IL-4 and / or IL-13 to their respective receptors
ES2823563T3 (en) *	2014-05-22	2021-05-07	Pieris Pharmaceuticals Gmbh	Novel specific binding polypeptides and uses thereof
EA201890198A1 (en)	2015-07-15	2018-07-31	ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ	NEW PROTEINS SPECIFIC FOR THE LAG-3
CN107474134B (en) *	2016-06-08	2021-07-27	苏州康乃德生物医药有限公司	Antibodies for binding interleukin-4 receptor
MX2019008434A (en)	2017-01-18	2019-11-11	Pieris Pharmaceuticals Gmbh	Lipocalin muteins with binding affinity for lag-3.
MX2019012570A (en) *	2017-04-21	2019-12-02	Kindred Biosciences Inc	Il4/il13 receptor molecule for veterinary use.
CN111494625B (en) *	2018-12-25	2022-06-21	江苏荃信生物医药股份有限公司	Pharmaceutical compositions for the treatment of IL-4 and/or IL-13 mediated signal transduction related disorders
CN113613669A (en) *	2019-03-29	2021-11-05	阿斯利康有限公司	Lipocalin muteins for the treatment of asthma
CA3127973A1 (en)	2019-03-29	2020-10-08	Pieris Pharmaceuticals Gmbh	Inhaled administration of lipocalin muteins
TW202241490A (en)	2020-12-18	2022-11-01	瑞典商阿斯特捷利康公司	Lipocalin mutein dry powder formulation for treatment of asthma
CN115414467B (en) *	2022-10-14	2023-06-06	中国人民解放军陆军军医大学第二附属医院	Application of apolipoprotein D in preparation of medicine for treating cerebral hemorrhage

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH01215289A (en)	1988-02-22	1989-08-29	Toa Nenryo Kogyo Kk	Production of normal human serum albumin a through gene recombination
FR2649991B2 (en)	1988-08-05	1994-03-04	Rhone Poulenc Sante	USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES
US5728553A (en)	1992-09-23	1998-03-17	Delta Biotechnology Limited	High purity albumin and method of producing
DE4425255A1 (en)	1994-07-16	1996-01-18	Asta Medica Ag	Formulation for inhalation application
US5908621A (en)	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
US6446467B1 (en)	1997-07-29	2002-09-10	Physical Optics Corporation	Monolithic glass light shaping diffuser and method for its production
DE19742706B4 (en)	1997-09-26	2013-07-25	Pieris Proteolab Ag	lipocalin muteins
JP3839667B2 (en)	1998-06-08	2006-11-01	エフ．ホフマン−ラロシュアーゲー	Use of Peg-INF-alpha and ribavirin for the treatment of chronic hepatitis C
US6403564B1 (en)	1998-10-16	2002-06-11	Schering Corporation	Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (en)	1999-06-08	2001-01-11	Arne Skerra	Muteins of the bilin binding protein
DE10043509A1 (en)	2000-09-01	2002-03-14	Asta Medica Ag	Solid peptide preparations for inhalation and their manufacture
AU2002335930B2 (en)	2001-03-09	2005-07-28	Morphosys Ag	Serum albumin binding moieties
WO2003029462A1 (en)	2001-09-27	2003-04-10	Pieris Proteolab Ag	Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2001298053A1 (en)	2001-09-27	2003-04-14	Pieris Proteolab Ag	Muteins of apolipoprotein D
AU2003233583A1 (en) *	2002-05-24	2003-12-12	Agennix Incorporated	Oral lactoferrin in the treatment of respiratory disorders
AU2003275958A1 (en)	2003-08-25	2005-03-10	Pieris Proteolab Ag	Muteins of tear lipocalin
US7691970B2 (en)	2003-08-25	2010-04-06	Pieris Ag	Muteins of a bilin-binding protein with affinity for a given target
RU2389796C2 (en)	2003-08-29	2010-05-20	Аэровэнс, Инк.	Modified antagonist of receptor il-4 and purified polynucleotide intended for its production
US7892827B2 (en)	2004-11-26	2011-02-22	Pieris Ag	Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
AU2006294644A1 (en)	2005-09-27	2007-04-05	Amunix, Inc.	Proteinaceous pharmaceuticals and uses thereof
WO2007107563A2 (en)	2006-03-20	2007-09-27	Technische Universität München	Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
WO2008015239A2 (en)	2006-08-01	2008-02-07	Pieris Ag	Muteins of tear lipocalin and methods for obtaining the same
JP2010533204A (en) *	2007-07-11	2010-10-21	アエロヴァンスインコーポレイティッド	Pharmaceutical polypeptide dry powder aerosol formulation and method for its preparation
HUE043835T2 (en)	2010-06-08	2019-09-30	Pieris Pharmaceuticals Gmbh	Tear lipocalin muteins binding il-4 r alpha
DK2790719T3 (en)	2011-12-13	2019-02-11	Pieris Pharmaceuticals Gmbh	Methods for preventing or treating certain diseases by inhibiting the binding of IL-4 and / or IL-13 to their respective receptors

2012
- 2012-12-12 DK DK12813295.8T patent/DK2790719T3/en active
- 2012-12-12 SG SG10201604566QA patent/SG10201604566QA/en unknown
- 2012-12-12 EP EP18197286.0A patent/EP3453400B1/en active Active
- 2012-12-12 CA CA2858962A patent/CA2858962C/en active Active
- 2012-12-12 HU HUE18197286A patent/HUE054342T2/en unknown
- 2012-12-12 HU HUE12813295A patent/HUE042720T2/en unknown
- 2012-12-12 WO PCT/EP2012/075146 patent/WO2013087660A1/en active Application Filing
- 2012-12-12 TR TR2019/01826T patent/TR201901826T4/en unknown
- 2012-12-12 EP EP21152253.7A patent/EP3842058B1/en active Active
- 2012-12-12 AU AU2012350660A patent/AU2012350660B2/en active Active
- 2012-12-12 EP EP12813295.8A patent/EP2790719B1/en active Active
- 2012-12-12 PL PL18197286T patent/PL3453400T3/en unknown
- 2012-12-12 US US14/364,449 patent/US9572863B2/en active Active
- 2012-12-12 ES ES18197286T patent/ES2863410T3/en active Active
- 2012-12-12 ES ES12813295T patent/ES2710384T3/en active Active
- 2012-12-12 PL PL12813295T patent/PL2790719T3/en unknown
- 2012-12-12 CN CN201280061754.7A patent/CN103998053B9/en active Active
- 2012-12-12 SG SG11201402992SA patent/SG11201402992SA/en unknown
- 2012-12-12 JP JP2014546471A patent/JP6163162B2/en active Active
- 2012-12-12 DK DK18197286.0T patent/DK3453400T3/en active
- 2012-12-12 CN CN201811146540.5A patent/CN109432402B/en active Active
2016
- 2016-12-02 US US15/367,680 patent/US10016483B2/en active Active
2017
- 2017-03-30 JP JP2017067615A patent/JP6725447B2/en active Active
2018
- 2018-06-07 US US16/002,704 patent/US10398754B2/en active Active
2019
- 2019-03-28 JP JP2019062186A patent/JP6889201B2/en active Active
- 2019-07-16 US US16/513,636 patent/US10857202B2/en active Active
2020
- 2020-05-27 JP JP2020092168A patent/JP2020164532A/en active Pending
- 2020-11-05 US US17/090,571 patent/US11382951B2/en active Active
2022
- 2022-03-25 JP JP2022049676A patent/JP7441589B2/en active Active
- 2022-06-14 US US17/839,635 patent/US20230021168A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TR201901826T4 (en)	2019-03-21
PL2790719T3 (en)	2019-05-31
US11382951B2 (en)	2022-07-12
JP2015505303A (en)	2015-02-19
ES2863410T3 (en)	2021-10-11
CN103998053B (en)	2018-11-02
CN103998053A (en)	2014-08-20
JP6889201B2 (en)	2021-06-18
US10857202B2 (en)	2020-12-08
JP7441589B2 (en)	2024-03-01
US10016483B2 (en)	2018-07-10
DK3453400T3 (en)	2021-04-06
JP2019116499A (en)	2019-07-18
US10398754B2 (en)	2019-09-03
CN103998053B9 (en)	2020-07-21
DK2790719T3 (en)	2019-02-11
SG11201402992SA (en)	2014-07-30
US20200009223A1 (en)	2020-01-09
CN109432402B (en)	2022-04-29
HUE042720T2 (en)	2019-07-29
US20190030121A1 (en)	2019-01-31
JP2017149733A (en)	2017-08-31
CA2858962C (en)	2023-09-05
US20210145934A1 (en)	2021-05-20
CA2858962A1 (en)	2013-06-20
EP3453400A1 (en)	2019-03-13
CN109432402A (en)	2019-03-08
US9572863B2 (en)	2017-02-21
EP3842058B1 (en)	2023-08-23
US20170112900A1 (en)	2017-04-27
PL3453400T3 (en)	2021-08-09
JP6163162B2 (en)	2017-07-12
AU2012350660B2 (en)	2018-01-25
JP6725447B2 (en)	2020-07-15
EP2790719B1 (en)	2018-11-21
US20230021168A1 (en)	2023-01-19
EP3842058A1 (en)	2021-06-30
JP2022084854A (en)	2022-06-07
US20140357548A1 (en)	2014-12-04
JP2020164532A (en)	2020-10-08
ES2710384T3 (en)	2019-04-24
EP2790719A1 (en)	2014-10-22
HUE054342T2 (en)	2021-08-30
AU2012350660A1 (en)	2014-07-03
WO2013087660A1 (en)	2013-06-20
EP3453400B1 (en)	2021-01-20

Publication	Publication Date	Title
SG10201604566QA (en)	2016-07-28	Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
IL288048A (en)	2022-01-01	Methods of treating or preventing cholesterol related disorders
ZA201606957B (en)	2018-05-30	Biguanide compositions and methods of treating metabolic disorders
IL226401A0 (en)	2013-07-31	Methods of treating fgf21-associated disorders
HK1206260A1 (en)	2016-01-08	Compositions and methods of use for treating metabolic disorders
ZA201308421B (en)	2016-01-27	Compositions uses and methods for treatment of metabolic disorders and diseases
HK1258530A1 (en)	2019-11-15	Serpina 1 sirnas: compositions of matter and methods of treatment
EP2852388A4 (en)	2016-01-13	Compounds and methods of use thereof for treating neurodegenerative disorders
EP2776567A4 (en)	2015-12-30	Compositions and methods for treatment of cytomegalovirus
EP2771030A4 (en)	2015-07-22	Compositions and methods for treatment of proteinopathies
EP2684167A4 (en)	2014-10-15	Compositions and methods useful for treating diseases
PT3272342T (en)	2021-07-12	Methods and compositions for treatment of attention deficit disorder
HK1198328A1 (en)	2015-04-02	Methods and compositions for treating asthma using anti-il-13 antibodies il-13
EP2691529A4 (en)	2014-12-10	Methods and compositions for treating brain diseases
IL230433A0 (en)	2014-03-31	Methods of treating pain
IL232190A0 (en)	2014-06-30	Methods of treating inflammatory disorders using anti-m-csf antibodies
EP2550361A4 (en)	2014-04-30	Compositions and methods for treating neurological disorders
IL229705A0 (en)	2014-01-30	Methods of treating or preventing neurological diseases
EP2709466A4 (en)	2014-11-12	Method of treating honey
EP2673372A4 (en)	2014-11-19	Methods of prognosing and administering treatment for inflammatory disorders
IL227703A0 (en)	2013-09-30	Substituted aromatic sulfur compounds and methods of their use
IL227921A0 (en)	2013-09-30	Methods of prognosing and administering treatment for inflammatory disorders
GB201119458D0 (en)	2011-12-21	Compositions for treatment of sleep disorders